89bio to Present Additional Pegozafermin Data in Severe Hypertriglyceridemia from Phase 2 ENTRIGUE Study at American College of Cardiology's Annual Scientific Session Together with World Congress of Cardiology
89bio, Inc. (Nasdaq: ETNB), a biopharmaceutical company, announced new data from its Phase 2 ENTRIGUE study on pegozafermin for treating severe hypertriglyceridemia (SHTG). The findings will be showcased at the American College of Cardiology's 72nd Annual Scientific Session in New Orleans from March 4-6, 2023. The study, titled 'Pegozafermin Provides Beneficial Lipid Effects in Subjects with Severe Hypertriglyceridemia,' indicates that the treatment could yield significant lipid benefits, regardless of patients' background lipid-modifying therapy. The poster presentation is scheduled for March 4, 2023.
- Presentation of new data from the Phase 2 ENTRIGUE study may enhance investor confidence.
- Potential for pegozafermin to provide significant lipid effects in SHTG patients could lead to a strong market position.
- None.
SAN FRANCISCO, Feb. 21, 2023 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced additional pegozafermin data from the Phase 2 ENTRIGUE study in severe hypertriglyceridemia (SHTG) will be presented at the American College of Cardiology’s 72nd Annual Scientific Session Together with World Congress of Cardiology to be held March 4-6, 2023 in New Orleans.
Presentation details are as follows:
Abstract Title: Pegozafermin Provides Beneficial Lipid Effects in Subjects with Severe Hypertriglyceridemia (SHTG) Regardless of Background Lipid Modifying Therapy Status: An Analysis of the Phase 2 ENTRIGUE Study
Poster Number: 184
Format: Poster presentation
Session: 1314 - Prevention and Health Promotion: Lipids 4
Presenting Authors: Deepak L. Bhatt, M.D., M.P.H., Director of Mount Sinai Heart and, Valentin Fuster, M.D., Ph.D., Professor of Cardiovascular Medicine, Icahn School of Medicine at Mount Sinai Health System
Presentation Date and Time: Saturday, March 4, 12:45-1:30 p.m. CT
About 89bio
89bio is a clinical-stage biopharmaceutical company dedicated to the development of best-in-class therapies for patients with liver and cardiometabolic diseases who lack optimal treatment options. The company is focused on rapidly advancing its lead candidate, pegozafermin, through clinical development for the treatment of non-alcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG). Pegozafermin is a specifically engineered, potentially best-in-class fibroblast growth factor 21 (FGF21) analog with unique glycoPEGylated technology that optimizes biological activity through an extended half-life. The company is headquartered in San Francisco. For more information, visit www.89bio.com or follow the company on LinkedIn.
Investor Contact:
Ryan Martins
Chief Financial Officer
investors@89bio.com
PJ Kelleher
LifeSci Advisors, LLC
+1-617-430-7579
pkelleher@lifesciadvisors.com
Media Contact:
Sheryl Seapy
Real Chemistry
sseapy@realchemistry.com
FAQ
What new data did 89bio announce regarding pegozafermin?
When and where will the pegozafermin data be presented?
What is the focus of the Phase 2 ENTRIGUE study?
Why is the presentation of the ENTRIGUE study data important for investors?
What is pegozafermin and its significance in liver and cardiometabolic diseases?
